1. Home
  2. FRES vs LGVN Comparison

FRES vs LGVN Comparison

Compare FRES & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FRES
  • LGVN
  • Stock Information
  • Founded
  • FRES 2010
  • LGVN 2014
  • Country
  • FRES United States
  • LGVN United States
  • Employees
  • FRES N/A
  • LGVN N/A
  • Industry
  • FRES Medical Specialities
  • LGVN Medicinal Chemicals and Botanical Products
  • Sector
  • FRES Health Care
  • LGVN Health Care
  • Exchange
  • FRES Nasdaq
  • LGVN Nasdaq
  • Market Cap
  • FRES 70.9M
  • LGVN 7.8M
  • IPO Year
  • FRES 2020
  • LGVN 2021
  • Fundamental
  • Price
  • FRES $2.65
  • LGVN $3.52
  • Analyst Decision
  • FRES
  • LGVN Strong Buy
  • Analyst Count
  • FRES 0
  • LGVN 1
  • Target Price
  • FRES N/A
  • LGVN $12.00
  • AVG Volume (30 Days)
  • FRES 10.5K
  • LGVN 10.2M
  • Earning Date
  • FRES 07-30-2024
  • LGVN 08-09-2024
  • Dividend Yield
  • FRES N/A
  • LGVN N/A
  • EPS Growth
  • FRES N/A
  • LGVN N/A
  • EPS
  • FRES N/A
  • LGVN N/A
  • Revenue
  • FRES $2,345,304.00
  • LGVN $978,000.00
  • Revenue This Year
  • FRES N/A
  • LGVN $137.24
  • Revenue Next Year
  • FRES N/A
  • LGVN $50.77
  • P/E Ratio
  • FRES N/A
  • LGVN N/A
  • Revenue Growth
  • FRES N/A
  • LGVN N/A
  • 52 Week Low
  • FRES $2.50
  • LGVN $0.77
  • 52 Week High
  • FRES $41.80
  • LGVN $36.50
  • Technical
  • Relative Strength Index (RSI)
  • FRES 35.87
  • LGVN 60.33
  • Support Level
  • FRES $2.50
  • LGVN $3.80
  • Resistance Level
  • FRES $3.40
  • LGVN $6.40
  • Average True Range (ATR)
  • FRES 0.41
  • LGVN 0.57
  • MACD
  • FRES -0.03
  • LGVN 0.20
  • Stochastic Oscillator
  • FRES 11.81
  • LGVN 41.70

About FRES Fresh2 Group Limited

Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Share on Social Networks: